Turning Stem Cells into Ear Cells
News Sep 13, 2012
Transplantation of the auditory neurons into deaf gerbils, improved their hearing by 46% on average. Improvements were first seen about four weeks after treatment.
As well as proving that stem cells can be used to repair damaged hearing, it is hoped the breakthrough – published in the journal Nature – will lead to new cell-based therapies in the future for some forms of deafness.
'Important step forward'
Dr Marcelo Rivolta, who led the project, said: 'We believe this is an important step forward. We now have a method to produce human cochlear sensory cells that we could use to develop new drugs and treatments, and to study the function of genes. And more importantly, we have the proof-of-concept that human stem cells could be used to repair the damaged ear.
'More research is needed. For instance, we want to understand the long term implications of this treatment and its safety.'
Dr Ralph Holme, Head of Biomedical Research for Action on Hearing Loss, said: 'The research we have funded at the University of Sheffield(opens in new window) is tremendously encouraging and gives us real hope that it will be possible to fix the actual cause of some types of hearing loss in the future. For the millions of people for whom hearing loss is eroding their quality of life, this can’t come soon enough.
'Today's cochlear implants provide a sensation of hearing, but they need a healthy auditory nerve to stimulate. By combining these devices with a therapy that repairs the auditory nerve many more people might be able to benefit from cochlear implant technology in the future.'
For information about how Action on Hearing Loss is funding biomedical research to develop treatments to improve the everyday lives of people with hearing loss.
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Gilead Company Wins FDA Approval for CAR T Cancer Therapy for Treatment of Adult LymphomaNews
Kite’s Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.READ MORE